Twist Bioscience Stock Price, News & Analysis

Twist Bioscience (NASDAQ: TWST) and Ginkgo Bioworks (NYSE: DNA) have revised their 2022 collaboration agreement with new terms. The updated three-year $15 million agreement maintains Ginkgo as a valued customer of Twist's DNA products with preferential pricing and no minimum purchase requirements. As part of the deal, Twist receives licenses and assignments for long DNA technology and related reagents, while Ginkgo retains rights to practice the transferred IP. The agreement involves annual prepayments from Ginkgo for Twist's DNA products.

Twist Bioscience (NASDAQ: TWST) announced its fiscal 2025 second quarter financial results, with the earnings call scheduled for 8:00 a.m. Eastern Time. The company will host a conference call and live audio webcast for analysts and investors to discuss the financial performance and provide business updates. Interested participants can register through the company's Investor Relations website to receive dial-in information. A webcast replay will be available for two weeks following the call.

Twist Bioscience (NASDAQ: TWST) has announced the spin-out of its DNA data storage technology into a new independent company called Atlas Data Storage. The spin-out is backed by $155 million in seed financing from notable investors including ARCH Venture Partners, Deerfield Management, and Bezos Expeditions. Varun Mehta, former founder of Nimble Storage, will serve as CEO of Atlas. Under the agreement, Twist will maintain a minority stake in Atlas and receive an upfront cash payment, a secured promissory note, potential milestone payments, and royalties on future sales. The transaction allows Twist to focus on its core life sciences business, with expectations to achieve adjusted EBITDA breakeven by the end of fiscal 2026. The new company will operate independently, with Emily Leproust serving on Atlas's board and Bill Banyai, Twist co-founder, moving to Atlas as CTO.

Twist Bioscience (NASDAQ: TWST) has expanded its NGS tools portfolio with the launch of an enhanced High Throughput (HT) Unique Dual Index (UDI) Adapter System. The company has doubled its high throughput offering to 3,072 HT UDI Adapters, enabling researchers to multiplex and process thousands of samples simultaneously.

The expanded adapter system is designed for large-scale population studies, genetic biomarker validation, and therapeutic target screening. The HT UDIs are 12 base pairs in length, come in 10 um concentration, and are available in automation-friendly 96 or 384 well plate configurations. All indexes are optimized for both two-color and four-color chemistries with balanced base and color channels.

Twist Bioscience (NASDAQ: TWST) has announced it will release its fiscal 2025 second quarter financial results on Monday, May 5, 2025, before market opening. The company will host a conference call and live audio webcast for analysts and investors at 8:00 AM Eastern Time to discuss the quarterly results and provide a business update.

Participants interested in joining via telephone must pre-register through the company's Investor Relations website. The financial results press release will be available on the company's website in the Investor Relations section. A webcast replay will be accessible for two weeks following the call.

Twist Bioscience (NASDAQ: TWST) and Curio Genomics have announced a strategic collaboration to accelerate NGS (Next-Generation Sequencing) adoption in agricultural genomics. The partnership combines Twist's FlexPrep™ Ultra-High Throughput Library Preparation Kit with Curio's bioinformatics software platform.

The collaboration aims to overcome traditional barriers in NGS adoption for agrigenomics, where microarray workflows have dominated due to lower costs and familiarity. The integrated solution offers:

• High-throughput genotyping capabilities for thousands of samples
• Streamlined workflow with improved economics
• Ability to generate high complexity libraries for low pass whole genome sequencing
• All-in-one genotyping, marker discovery, and fine mapping
• Compatibility with historical microarray data

The Twist FlexPrep™ UHT Kit features Normalization by Ligation™ technology, eliminating the need for individual DNA sample measurements and concentration adjustments, resulting in significant cost savings per sample.

Twist Bioscience (NASDAQ: TWST) has announced a -time offer for academic customers globally, providing Express Genes orders with expedited shipping in as few as four days at no additional cost. This initiative aims to support research institutions facing budget constraints while maintaining scientific progress.

The Express Genes offering includes:

• Gene lengths ranging from 0.3kb to 5.0kb
• NGS sequence verification with 100% accuracy
• Flexibility in order volume
• Options for cloning into catalog or custom vectors
• Multiple delivery format options including tubes and plates

This move represents Twist's commitment to supporting academic research by eliminating premium charges for rapid turnaround times, helping institutions maximize their research budgets.

Twist Bioscience (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, has announced its executives' participation in upcoming investor conferences.

The schedule includes:

• Emily Leproust, Ph.D., CEO and co-founder, and Adam Laponis, CFO, at the TD Cowen 45th Annual Health Care Conference on March 4 in Boston (fireside chat at 1:50 pm ET)
• Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, at the Leerink Global Biopharma Conference 2025 on March 11 in Miami (fireside chat at 9:20 am ET)
• Patrick Finn and Adam Laponis at the Barclays Global Healthcare Conference 2025 on March 12 in Miami (fireside chat at 8:30 am ET)

All fireside chats will be webcast live through the investor relations section of the company's website and archived for 30 days after the events.

Twist Bioscience (NASDAQ: TWST) has announced the granting of 123,024 equity awards to 32 newly hired employees as employment inducements. The awards consist of 72,394 restricted stock units (RSUs) and up to 50,630 performance stock units (PSUs).

The RSUs will vest over 48 months, with 25% vesting after one year and 1/16 vesting quarterly thereafter. The PSUs will vest based on performance metrics set by the Board's Compensation Committee, achievable by the end of fiscal 2027 at 50%-140% of target. Both are subject to continued employment.

These awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4) for new hires or those returning after non-employment periods.